Evidence map›Paper›PMID 41951736›Full record

ArticleNature2026

Clinical application of base editing for treating β-thalassaemia.

Yongrong Lai, Rongrong Liu, Lijie Wang, Xu-Kai Ma, Yaliang Li, Gaohui Yang, Lingling Shi, Yi-Lin Guo, Zhenbin Wei, Xuemei Zhou and 7 more

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Engineered Transformer Base Editor with Enhanced Editing Efficiency.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. The landscape and trajectory of global CRISPR therapeutics.Molecular therapy. Nucleic acids · 2026
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yongrong Lai *Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. laiyongrong@hotmail.com.ORCID http://orcid.org/0000-0002-0371-1719
Rongrong Liu *Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Lijie Wang *Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Xu-Kai Ma *Center for Molecular Medicine, Children's Hospital of Fudan University and Shanghai Key Laboratory of Medical Epigenetics, International Laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Yaliang LiCorrectSequence Therapeutics, Shanghai, China.
Gaohui YangDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Lingling ShiDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yi-Lin GuoCenter for Molecular Medicine, Children's Hospital of Fudan University and Shanghai Key Laboratory of Medical Epigenetics, International Laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Zhenbin WeiDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xuemei ZhouDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Wenchao XuGene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Yaofeng HouGene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Annarita MiccioUniversité Paris Cité, Imagine Institute, Laboratory of Chromatin And Gene Regulation During Development, INSERM UMR 1163, Paris, France.ORCID http://orcid.org/0000-0002-3409-9665
Bei YangGene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.ORCID http://orcid.org/0000-0001-5389-3859
Xiaodun MouCorrectSequence Therapeutics, Shanghai, China. susan.mou@correctsequence.com.ORCID http://orcid.org/0009-0007-5449-712X
Li YangCenter for Molecular Medicine, Children's Hospital of Fudan University and Shanghai Key Laboratory of Medical Epigenetics, International Laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, China. liyang_fudan@fudan.edu.cn.ORCID http://orcid.org/0000-0001-8833-7473
Jia ChenGene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China. chenjia@shanghaitech.edu.cn.ORCID http://orcid.org/0000-0002-4242-2899

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

β-Thalassaemia is caused by reduced or absent production of β-haemoglobin

Indexed as

beta-ThalassemiaGene EditingAdolescentAdultAntigens, CD34Carrier ProteinsChildErythrocyte TransfusionFemaleFetal HemoglobinFollow-Up Studiesgamma-GlobinsHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHumansMaleAntigens, CD34BCL11A protein, humanCarrier ProteinsFetal Hemoglobingamma-GlobinsNuclear ProteinsRepressor Proteins

Identifiers

PMID41951736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.